

1 Assessment of Commercial SARS-CoV-2 Antibody Assays, Jamaica

2

3 Tiffany R. Butterfield<sup>a,1</sup>, Alrica Bruce-Mowatt<sup>a,1</sup>, Yakima Z. R. Phillips<sup>a</sup>, Nicole Brown<sup>a</sup>, Keisha

4 Francis<sup>a</sup>, Jabari Brown<sup>b</sup>, Devon Taylor<sup>c</sup>, Carl A. Bruce<sup>d</sup>, Donovan McGrowder<sup>b</sup>, Gilian Wharfe<sup>b</sup>,

5 Simone L. Sandiford<sup>e</sup>, Tamara K. Thompson<sup>f</sup>, Joshua J. Anzinger<sup>a,g\*</sup>

6

7 <sup>a</sup>The University of the West Indies, Department of Microbiology, Kingston, Jamaica, West

8 Indies

9 <sup>b</sup>The University of the West Indies, Department of Pathology, Kingston, Jamaica, West Indies

10 <sup>c</sup>AstraZeneca, Department of Oncology Research, Gaithersburg, Maryland, United States of

11 America

12 <sup>d</sup>The University of the West Indies, Department of Surgery, Kingston, Jamaica, West Indies

13 <sup>e</sup>The University of the West Indies, Department of Basic Medical Sciences, Kingston, Jamaica,

14 West Indies

15 <sup>f</sup>The University of the West Indies, Department of Medicine, Kingston, Jamaica, West Indies

16 <sup>g</sup>Global Virus Network, Baltimore, MD, United States of America

17

18 <sup>1</sup>Equal contribution

19

20 \*Corresponding Author. Email address [joshua.anzinger@uwimona.edu.jm](mailto:joshua.anzinger@uwimona.edu.jm) (J. Anzinger)

21

22

23 Word Count: 1230

24 **Abstract**

25 The performance of the Roche Elecsys<sup>®</sup> Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2  
26 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium  
27 IgG/IgM rapid assays was evaluated in Jamaica, the largest country of the English-speaking  
28 Caribbean. Diagnostic sensitivities of the assays were assessed by testing serum samples from  
29 SARS-CoV-2 PCR-confirmed persons. Serum samples collected  $\geq 14$  days after onset of  
30 symptoms, or  $\geq 14$  days after an initial SARS-CoV-2 RT-PCR positive test for asymptomatics,  
31 showed diagnostic sensitivities ranging from 67.9-75.0% when including all possible disease  
32 severities and increased to 90.0-95.0% when examining those with moderate to critical disease.  
33 Grouping moderate to critical disease showed a significant association with a SARS-CoV-2  
34 antibody positive result for all assays. Diagnostic specificity, assessed by testing serum samples  
35 collected during 2018-2019 from healthy persons and from persons with antibodies to a wide  
36 range of viral infections, ranged from 96.7-100.0%. For all assays examined, SARS-CoV-2 real-  
37 time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive  
38 were significantly different for samples testing antibody positive versus negative. These data  
39 from a predominantly African descent Caribbean population shows comparable diagnostic  
40 sensitivities and specificities for all testing platforms assessed and limited utility of these tests for  
41 persons with asymptomatic and mild infections.

42

43

44 **Keywords:** COVID-19; SARS-CoV-2; Antibody; Serology; Caribbean; Jamaica

## 45 **1. Introduction**

46 The SARS-CoV-2 pandemic has resulted in an unprecedented need for reliable commercial  
47 laboratory diagnostics. While SARS-CoV-2 antibody assays have recently become commercially  
48 available, performance data have mainly assessed high-income country populations. Assessment  
49 of SARS-CoV-2 antibody assay performance in populations of mostly African descent is  
50 lacking. To our knowledge, there has been no published performance assessment of SARS-CoV-  
51 2 antibody assays with a predominantly black population. In this study in Jamaica, serum  
52 samples were used to assess the diagnostic sensitivity and specificity of five commercial SARS-  
53 CoV-2 antibody assays: Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2  
54 IgG, Euroimmun SARS-CoV-2 IgA and IgG ELISAs, and Trillium IgG/IgM rapid diagnostic  
55 test.

## 56 57 **2. Materials and methods**

58 For diagnostic sensitivity analysis, 42 blood samples collected in tubes without coagulant were  
59 obtained from 37 consenting persons testing SARS-CoV-2 real-time PCR positive. Disease  
60 severity was classified according to WHO criteria. Real-time PCR of nasopharyngeal swabs  
61 samples was performed at the Jamaica National Influenza Centre according to the Corman *et al*  
62 method [1]. Samples were collected 6-103 days after disease onset for symptomatic persons and  
63 20-69 days after a positive real-time PCR test for asymptomatic persons.

64 For the assessment of diagnostic specificity, archival 2018-2019 serum samples from the  
65 University of the West Indies Virology Laboratory were identified. All samples were stored at -  
66 20°C. The specificity panel included serum samples testing positive for Zika virus IgM,  
67 chikungunya virus IgM, dengue virus IgM, CMV IgM, CMV IgG, EBV IgM, parvovirus B19

68 IgM, anti-HTLV-I/II, HIV Ag/Ab, HBsAg, anti-HCV, convalescent samples from patients  
69 seroconverting for influenza A or B virus antibodies, convalescent samples from patients with  
70 respiratory disease but without seroconversion for influenza A and B virus antibodies, healthy  
71 persons requesting vaccination status, and women seeking routine antenatal care (Supplementary  
72 Table).

73  
74 The detection of antibodies was conducted with an Architect *i2000SR* for the Architect SARS-  
75 CoV-2 IgG assay, a cobas<sup>®</sup> 6000 analyzer for the Elecsys<sup>®</sup> Anti-SARS-CoV-2 assay, a Thermo  
76 Scientific Multiskan FC Microplate Photometer for the Euroimmun SARS-CoV-2 IgA and IgG  
77 ELISAs and lateral flow assay rapid test for the Trillium IgG/IgM assay. Each manufacturer's  
78 instructions were used for cutoff index values for the Elecsys<sup>®</sup>, Architect, and Euroimmun  
79 platforms, and the appearance of a line of any intensity for the control and/or IgG and IgM for  
80 the Trillium IgG/IgM rapid test. Index values  $\geq 1.0$  are considered positive and index values  $< 1.0$   
81 are considered negative for the Elecsys<sup>®</sup> Anti-SARS-CoV-2 assay. For the Architect SARS-  
82 CoV-2 IgG assay index values  $\geq 1.4$  are considered positive and index values  $< 1.4$  are considered  
83 negative. For both Euroimmun SARS-CoV-2 ELISAs, index values  $\geq 1.1$  are considered positive,  
84  $\geq 0.8$ - $< 1.1$  are considered borderline, and  $< 0.8$  are considered negative. Borderline index values  
85 were considered negative.

86  
87 Data were analyzed using IBM SPSS Statistics<sup>®</sup> for Windows version 20. Categorical variables  
88 were reported using proportions and continuous variables reported as mean with standard  
89 deviation. Comparison of means was by Welch's t-test while associations between categorical  
90 variables were assessed using the  $\chi^2$  test.

91

92 This study was approved by the UWI Mona Campus Research Ethics Committee (ECP 244  
93 19/20).

94

### 95 **3. Results**

96 Diagnostic specificity of each assay was examined with a panel of archived serum samples  
97 predating the introduction of SARS-CoV-2 into Jamaica. The specificity was 100.0% (104/104)  
98 for Elecsys<sup>®</sup> Anti-SARS-CoV-2, 98.2% (109/111) for Architect SARS-CoV-2 IgG, 97.5%  
99 (119/122) for Euroimmun SARS-CoV-2 IgA, 100.0% (122/122) for Euroimmun SARS-CoV-2  
100 IgG, 96.7% (87/90) for Trillium IgM, and 98.9% (89/90) for Trillium IgG (Supplementary  
101 Table).

102

103 Diagnostic sensitivities of the assays ranged from 42.9-71.4% for samples collected 6-9 days  
104 after onset of symptoms, 85.7-100.0% for samples collected 10-13 days after onset of symptoms,  
105 and 90.0-95.0% for samples collected  $\geq 14$  days after onset of symptoms (Fig. 1). As samples  
106 from asymptomatic and mildly affected persons were only available for collections  $\geq 14$  days  
107 after onset of symptoms or after an initial SARS-CoV-2 PCR test, we examined sensitivities for  
108 all disease severities separately. For all assays, sensitivities were lower when asymptomatic and  
109 mild infections were included, ranging from 67.9-75.0% (Fig. 1). When moderate, severe and  
110 critical disease was grouped, for each assay there was a significant association between this  
111 group and testing antibody positive: Elecsys<sup>®</sup> Anti-SARS-CoV-2 ( $\chi^2=19.03$ ,  $p=0.001$ ), Architect  
112 SARS-CoV-2 IgG ( $\chi^2=15.72$ ,  $p=0.003$ ), Euroimmun SARS-CoV-2 IgA ( $\chi^2=21.11$ ,  $p=0.007$ ),

113 Euroimmun SARS-CoV-2 IgG ( $\chi^2=18.77, p=0.016$ ), and Trillium IgM ( $\chi^2=11.59, p=0.021$ ) and  
114 IgG ( $\chi^2=17.20, p=0.002$ ). Detection of antibodies was highly congruent between assays (Fig. 2).

115  
116 The low diagnostic sensitivity across testing platforms for asymptomatic and mild SARS-CoV-2  
117 infections led us to question whether a relationship exists between the presence of antibodies and  
118 relative SARS-CoV-2 viral load at laboratory diagnosis. SARS-CoV-2 real-time PCR cycle  
119 threshold (Ct) values were compared with the presence of antibodies from patients with samples  
120 collected  $\geq 14$  days after onset of symptoms or an initial SARS-CoV-2 PCR. Ct values were  
121 significantly different between samples testing positive and negative for all assays examined  
122 (Fig. 3). For the Elecsys<sup>®</sup> Anti-SARS-CoV-2, Architect SARS-CoV-2 IgG, Euroimmun SARS-  
123 CoV-2 IgG, and Trillium IgG assays, the mean Ct value was  $23.5 \pm 5.7$  for samples testing  
124 antibody positive and  $34.6 \pm 1.0$  for samples testing antibody negative. Mean Ct values for  
125 Euroimmun IgA were  $24.0 \pm 5.7$  for samples testing antibody positive  $31.8 \pm 6.8$  for samples  
126 testing antibody negative, and for Trillium IgM,  $23.0 \pm 5.8$  for samples testing antibody positive  
127 and  $33.5 \pm 2.8$  for samples testing antibody negative.

128

#### 129 **4. Discussion and conclusions**

130 Our data examining two chemiluminescent assays, two ELISA assays and one rapid test show  
131 that the diagnostic sensitivity of these assays for SARS-CoV-2 antibodies is comparable. Each of  
132 the tests examined in this study are approved by the FDA and are CE marked, except for the new  
133 Trillium IgM/IgG rapid diagnostic test. The similar diagnostic sensitivity and specificity of the  
134 Trillium IgM/IgG rapid diagnostic test with chemiluminescent and ELISA assays makes this test

135 suitable for resource limited laboratories lacking high cost instruments and those that may run  
136 laboratory-based assays infrequently in batches.

137

138 An accumulating body of evidence indicates that after a SAR-CoV-2 infection antibodies  
139 become detectable approximately one week after disease onset [2]. In agreement with these  
140 studies, approximately half of the SARS-CoV-2 infected persons in our study had detectable  
141 antibodies 6-9 days after onset of symptoms, with most having antibodies  $\geq 10$  days after  
142 symptom onset.

143

144 The high sensitivities for moderate to critical SARS-CoV-2 infections for each of the assays  
145 examined is consistent with previous studies [2]. When asymptomatic and mild groups were  
146 included in our analysis, sensitivities decreased for all assays. Previous studies have shown that  
147 asymptomatic persons are less likely than symptomatic persons of having detectable SARS-  
148 CoV-2 antibodies [3,4].

149

150 Comparing SARS-CoV-2 antibody results revealed a striking difference in relative viral loads  
151 (Ct values) between persons testing antibody negative or positive, with patients testing antibody  
152 negative having significantly lower viral loads than patients testing antibody positive. These data  
153 are consistent with a recently published study examining SARS-CoV-2-infected asymptomatic  
154 contacts and outpatients showing that SARS-CoV-2 real-time PCR Ct values are inversely  
155 related to SARS-CoV-2 IgG index values using the Euroimmun SARS-CoV-2 IgG ELISA assay  
156 [4]. High SARS-CoV-2 viral loads could cause a more robust adaptive immune response leading  
157 to production of high levels and quality of SARS-CoV-2 antibodies.

158

159 Our data assessing a Caribbean population of predominantly African descent highlights the  
160 limited diagnostic sensitivity of the assays examined for persons with asymptomatic and mild  
161 SARS-CoV-2 infections. This finding has important implications for future seroprevalence  
162 studies in which a sizable proportion of the SARS-CoV-2-infected population may have  
163 experienced no symptoms or mild disease.

164

#### 165 **Declaration of competing interest**

166 All authors declared no conflict of interest.

167

#### 168 **Acknowledgements**

169 As a Global Infectious Diseases Scholar, Tiffany Butterfield received mentored research training  
170 in the development of this manuscript. This training was supported in part by the University at  
171 Buffalo Clinical and Translational Science Institute award UL1TR001412 and the Global  
172 Infectious Diseases Research Training Program award D43TW010919. The content is solely the  
173 responsibility of the authors and does not necessarily represent the official views of the Clinical  
174 and Translational Science Institute or the National Institutes of Health.


175

#### 176 **References**

- 177 1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of  
178 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020 Jan  
179 23;25(3):2000045.
- 180 2. Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Spijker R, Taylor-Phillips S, et al.




- 181           Antibody tests for identification of current and past infection with SARS-CoV-2.  
182           Cochrane Database Syst Rev. 2020;2(6):1–306.
- 183    3.    Wellinghausen N, Plonné D, Voss M, Ivanova R, Frodl R, Deininger S. SARS-CoV-2-IgG  
184           response is different in COVID-19 outpatients and asymptomatic contact persons. J Clin  
185           Virol. 2020 Sep 1;130:104542.
- 186    4.    Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological  
187           assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020;26(August).
- 188



189

190 **Fig. 1.** SARS-CoV-2 antibody index values by days after symptom onset for SARS-CoV-2 PCR  
 191 positive persons. Means with standard deviations are displayed for A) Elecsys® Anti-SARS-  
 192 CoV-2, B) Architect SARS-CoV-2 IgG, C) Euroimmun SARS-CoV-2 IgA, and D) Euroimmun  
 193 SARS-CoV-2 IgG assays. Horizontal dotted lines indicate cutoff values. For E) Trillium SARS-  
 194 CoV-2 IgM and F) Trillium SARS-CoV-2 IgG, white bars indicate the number of positive  
 195 samples and colored bars indicate samples testing negative. Disease severity is color coded as  
 196 follows: green = asymptomatic, blue = mild, orange = moderate, yellow = severe, and red =  
 197 critical.



198


199 **Fig. 2.** Agreement between SARS-CoV-2 antibody assays. Results for all samples tested for each

200 antibody testing platform are shown. Positive results are shown in white, borderline results in

201 light grey, and negative results in dark grey.

202

203



204

205 **Fig. 3.** SARS-CoV-2 PCR cycle threshold values for samples testing SARS-CoV-2 antibody  
206 negative or positive samples. Sera from SARS-CoV-2 RT-PCR confirmed persons was collected  
207  $\geq 14$  days after onset of symptoms or  $\geq 14$  after a positive SARS-CoV-2 RT-PCR test for  
208 asymptomatics. Results were identical for all platforms with the exception of Euroimmun SARS-  
209 CoV-2 IgA that tested borderline (open circle) and Trillium IgM that tested negative (open  
210 square). Differences between groups was highly significant for all testing platforms.  $p < 0.0001$   
211 for Elecsys<sup>®</sup> Anti-SARS-CoV-2, Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgG,  
212 and Trillium IgG.  $p < 0.0003$  for Euroimmun SARS-CoV-2 IgA and Trillium IgM.